Indications
Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Composition
- Active substance
- ruxolitinib phosphate
- International name (INN)
- ruxolitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Opzelura
- Active substance
- ruxolitinib phosphate
- ATC code
- D11AH
- Group
- Dermatologicals
- Therapeutic area
- Vitiligo
- Marketing authorisation holder
- Incyte Biosciences Distribution B.V.
- Status
- Authorised